Posted by Michael Wonder on 03 Sep 2018
Patients wanting special funding for anti-depressants turned down by PHARMAC
2 September 2018 - Last year, PHARMAC stopped subsidising two brands of anti-depressants, Arrow Venlafaxine and Effexor XR, and replaced them with a cheaper brand, Enlafax.
Some patients, who said they suffered adverse effects after changing the brand of antidepressants, had applied for special funding for their old brand, but been declined.
Under the Official Information Act, RNZ found 28 applications to PHARMAC for special funding for antidepressants that were no longer subsidised.
